Friday, July 10, 2026

Drug profile · INN

ciprofloxacin hydrochloride

ciprofloxacin hydrochloride (CIPROFLOXACIN HYDROCHLORIDE) is a bacterial dna gyrase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 8
Pipeline programs 23
News articles 0
Drug details — ciprofloxacin hydrochloride
US status
approved
Class
Route
OPHTHALMIC
Patents
8
Programs
23
Data quality
0.89

Quick answer

ciprofloxacin hydrochloride (CIPROFLOXACIN HYDROCHLORIDE) is a bacterial dna gyrase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN ciprofloxacin hydrochloride
Brand CIPROFLOXACIN HYDROCHLORIDE
Mechanism Bacterial DNA gyrase inhibitor
Target Bacterial DNA gyrase
Route OPHTHALMIC
Formulation TABLET

Mechanism of action

Bacterial DNA gyrase inhibitor

Primary target: Bacterial DNA gyrase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. APHP220763 Phase 3 · PARItec · Catheter related bloodstream infections due to Staphylococcu
  2. Ciprofloxacin (BAYQ3939) dry powder for inhalation Phase 3 · Bayer HealthCare Animal · Bronchiectasis
  3. M14-671 Phase 3 · AbbVie Deutschland GmbH · Crohn's Disease (CD)
  4. VACAB-2022 Phase 3 · George Institute for · Patients with hip or knee infections
  5. Vedolizumab-3041 Phase 3 · Takeda · Active Chronic Pouchitis
  6. Ciprofloxacin Phase 2 · United Therapeutics Europe · Crohn's Disease
  7. Fixed dose combination Ciprofloxacin/Celecoxib Phase 2 · NeuroSense Therapeutics · Amyotrophic Lateral Sclerosis
  8. Vociprotafib Phase 2 · Revolution Medicines · Metastatic Neoplasm

Related & competitor drugs

  1. cinoxacin Bacterial DNA gyrase inhibitor
  2. ciprofloxacin Bacterial DNA gyrase inhibitor
  3. moxifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  4. ofloxacin Bacterial DNA gyrase inhibitor
  5. alatrofloxacin mesylate Bacterial DNA gyrase inhibitor
  6. besifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  1. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12097185

    Compositions comprising ciprofloxacin and celecoxib

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11987590

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11168102

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11059830

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10948495

    Methods and reagents for analyzing protein-protein interfaces

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10533016

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10466249

    Methods and reagents for analyzing protein-protein interfaces

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ciprofloxacin hydrochloride?

ciprofloxacin hydrochloride (CIPROFLOXACIN HYDROCHLORIDE) is a bacterial dna gyrase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for ciprofloxacin hydrochloride?

CIPROFLOXACIN HYDROCHLORIDE is a marketed brand name for ciprofloxacin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ciprofloxacin hydrochloride?

ciprofloxacin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.